Last reviewed · How we verify

NCT03862235

Decreased T1 Times and Impaired Myocardial Contractility in Anabolic Androgenic Steroids Users

Completed Last updated 5 March 2019
What this trial tests

trial testing Cardiovascular Magnetic Resonance in Focal Fibrosis in 50 participants. Completed in 1 April 2017.

Timeline
1 April 2015
Primary endpoint
1 April 2016
1 April 2017

Quick facts

Lead sponsorUniversity of Sao Paulo General Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date1 April 2015
Primary completion1 April 2016
Estimated completion1 April 2017
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

University of Sao Paulo General Hospital

Who can join

Adults 18 to 45, male only, with Focal Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anabolic androgenic steroids (AAS) abuse may have a toxic on myocardium that could lead to cardiac alterations. Clinical cases reported myocardial fibrosis in AAS users. However, recent studies did not find myocardial fibrosis in AAS users using T1-mapping technique. The aim of this study was to evaluate cardiac structure by cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). We also evaluated the cardiac contractility in AAS users.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cardiovascular Magnetic Resonance

Trials testing the same drug.

Other University of Sao Paulo General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03862235.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing